73 related articles for article (PubMed ID: 16327305)
21. Association of E-cadherin gene 3'-UTR C/T polymorphism with calcium oxalate stone disease.
Tsai FJ; Wu HC; Chen HY; Lu HF; Hsu CD; Chen WC
Urol Int; 2003; 70(4):278-81. PubMed ID: 12740491
[TBL] [Abstract][Full Text] [Related]
22. P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype.
Rogler A; Rogenhofer M; Borchardt A; Lunz JC; Knoell A; Hofstaedter F; Tannapfel A; Wieland W; Hartmann A; Stoehr R
Pathobiology; 2011; 78(4):193-200. PubMed ID: 21778786
[TBL] [Abstract][Full Text] [Related]
23. Association of caspases with an increased prostate cancer risk in north Indian population.
Mittal RD; Mittal T; Singh AK; Mandal RK
DNA Cell Biol; 2012 Jan; 31(1):67-73. PubMed ID: 21668377
[TBL] [Abstract][Full Text] [Related]
24. Single nucleotide polymorphisms in the promoter region of the E-cadherin gene in gastric cancer: case-control study in a young Mexican population.
Medina-Franco H; Ramos-De la Medina A; Vizcaino G; Medina-Franco JL
Ann Surg Oncol; 2007 Aug; 14(8):2246-9. PubMed ID: 17549573
[TBL] [Abstract][Full Text] [Related]
25. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer.
Medeiros R; Vasconcelos A; Costa S; Pinto D; Lobo F; Morais A; Oliveira J; Lopes C
J Pathol; 2004 Mar; 202(3):330-5. PubMed ID: 14991898
[TBL] [Abstract][Full Text] [Related]
26. A functional polymorphism in MSMB gene promoter is associated with prostate cancer risk and serum MSMB expression.
Xu B; Wang J; Tong N; Mi Y; Min Z; Tao J; Li P; Cheng G; Li J; Wang M; Tang J; Song N; Zhang Z; Zhang W; Wu H; Hua L; Feng N
Prostate; 2010 Jul; 70(10):1146-52. PubMed ID: 20333697
[TBL] [Abstract][Full Text] [Related]
27. Pan-cadherin as a high level phenotypic biomarker for prostate cancer.
Wehbi NK; Dugger AL; Bonner RB; Pitha JV; Hurst RE; Hemstreet GP
J Urol; 2002 May; 167(5):2215-21. PubMed ID: 11956481
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D receptor polymorphisms and lethal prostate cancer.
Kibel AS; Isaacs SD; Isaacs WB; Bova GS
J Urol; 1998 Oct; 160(4):1405-9. PubMed ID: 9751364
[TBL] [Abstract][Full Text] [Related]
29. Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastatis.
Yigit B; Bozkurt N; Narter F; Yilmaz H; Yucebas E; Isbir T
Anticancer Res; 2007; 27(2):933-6. PubMed ID: 17465223
[TBL] [Abstract][Full Text] [Related]
30. A gain of function TGFB1 polymorphism may be associated with late stage prostate cancer.
Ewart-Toland A; Chan JM; Yuan J; Balmain A; Ma J
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):759-64. PubMed ID: 15159307
[TBL] [Abstract][Full Text] [Related]
31. Association of genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GSTP1) with familial prostate cancer risk in a Japanese population.
Nakazato H; Suzuki K; Matsui H; Koike H; Okugi H; Ohtake N; Takei T; Nakata S; Hasumi M; Ito K; Kurokawa K; Yamanaka H
Anticancer Res; 2003; 23(3C):2897-902. PubMed ID: 12926131
[TBL] [Abstract][Full Text] [Related]
32. Genetic polymorphisms of estrogen receptor alpha, CYP19, catechol-O-methyltransferase are associated with familial prostate carcinoma risk in a Japanese population.
Suzuki K; Nakazato H; Matsui H; Koike H; Okugi H; Kashiwagi B; Nishii M; Ohtake N; Nakata S; Ito K; Yamanaka H
Cancer; 2003 Oct; 98(7):1411-6. PubMed ID: 14508827
[TBL] [Abstract][Full Text] [Related]
33. TSP1 and MMP9 genetic variants in sporadic prostate cancer.
Sfar S; Saad H; Mosbah F; Gabbouj S; Chouchane L
Cancer Genet Cytogenet; 2007 Jan; 172(1):38-44. PubMed ID: 17175378
[TBL] [Abstract][Full Text] [Related]
34. Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease.
Ribeiro R; Vasconcelos A; Costa S; Pinto D; Morais A; Oliveira J; Lobo F; Lopes C; Medeiros R
Prostate; 2004 May; 59(3):268-74. PubMed ID: 15042602
[TBL] [Abstract][Full Text] [Related]
35. Polymorphic CAG/CAA repeat length in the AIB1/SRC-3 gene and prostate cancer risk: a population-based case-control study.
Hsing AW; Chokkalingam AP; Gao YT; Wu G; Wang X; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Chiang T; Chen YL; Stanczyk FZ; Chang C
Cancer Epidemiol Biomarkers Prev; 2002 Apr; 11(4):337-41. PubMed ID: 11927493
[TBL] [Abstract][Full Text] [Related]
36. Human kallikrein-2 gene polymorphism is associated with the occurrence of prostate cancer.
Chiang CH; Hong CJ; Chang YH; Chang LS; Chen KK
J Urol; 2005 Feb; 173(2):429-32. PubMed ID: 15643194
[TBL] [Abstract][Full Text] [Related]
37. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.
Safarinejad MR; Shafiei N; Safarinejad S
Growth Horm IGF Res; 2011 Jun; 21(3):146-54. PubMed ID: 21536469
[TBL] [Abstract][Full Text] [Related]
38. Association of genetic polymorphisms in vitamin D receptor gene and susceptibility to sporadic prostate cancer.
Onen IH; Ekmekci A; Eroglu M; Konac E; Yesil S; Biri H
Exp Biol Med (Maywood); 2008 Dec; 233(12):1608-14. PubMed ID: 18849534
[TBL] [Abstract][Full Text] [Related]
39. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
Sierra Díaz E; Sánchez Corona J; Rosales Gómez RC; Gutierrez Rubio SA; Vázquez Camacho JG; Solano Moreno H; Morán Moguel MC
J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):241-6. PubMed ID: 20026870
[TBL] [Abstract][Full Text] [Related]
40. Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer.
Chen YC; Giovannucci E; Lazarus R; Kraft P; Ketkar S; Hunter DJ
Cancer Res; 2005 Dec; 65(24):11771-8. PubMed ID: 16357190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
